Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Interleukin-2 treatment improved hair growth, sexual function, and reduced fungal infection in a patient with thymoma-related symptoms.

Sorafenib can cause a unique skin reaction.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

Cyclosporine combined with other treatments can help hair regrow in severe alopecia areata, but it may cause side effects.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Silicon may affect calcium metabolism in dialysis patients, causing symptoms like skin eruptions and abnormal hair growth.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

The mTOR signaling pathway might play a role in radiation dermatitis, but more research is needed.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

The drug combination was safe and showed promise in treating advanced tumors.

Almost all kidney transplant patients had complications from immunosuppressive therapy, with excessive hair growth being the most common.

Mesenchymal stem cells and their secretome may offer a safe and effective treatment for systemic lupus erythematosus.

Scientists improved an enzyme to better produce a hair growth-promoting chemical from an immunosuppressant.

Silymarin improved wound healing and skin regeneration in rats.

Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

The rash resolved after stopping ponatinib.